MRD-guided Treatment With Pembrolizumab and Azacitidine in NPM1mut AML Patients With an Imminent Hematological Relapse
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Feb 2019
At a glance
- Drugs Azacitidine (Primary) ; Pembrolizumab (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms PEMAZA
- 03 Jan 2019 Planned initiation date changed from 1 Dec 2018 to 1 Apr 2019.
- 14 Dec 2018 New trial record
- 11 Dec 2018 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.